Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ...

A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed ...

The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen ...

Hatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer ...

Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.

Regulators say the telehealth company illegally shared patients’ health data with advertisers and misled its customers. Hims ...

Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics "looms ...

In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the ...

The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss ...

Guido Oelkers will guide BioNTech’s ongoing transition into an oncology-focused biotech, while co-founder and longtime leader ...

The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster ...

Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall ...